A series of 2,4-diarylaminopyrimidine derivatives bearing hydrophilic hydroxamic acids were designed and synthesized as potent EGFR inhibitors. Among the derivatives synthesized, 10c (IC = 5.192 nM), 10j (IC = 10.35 nM), and 10o (IC = 0.3524 nM) exhibited higher potencies against EGFR compared to the known EGFR inhibitor AZD-9291 (IC = 20.80 nM). Moreover, 10j showed moderate activity against H1975 cells transfected with the EGFR mutant, with an IC of 0.2113 μM over A431 (wild-type EGFR, SI = 47.3). In addition, 10j exhibited low toxicity in normal HBE cells (human bronchial epithelial cells, IC > 40 μΜ). Analysis of the mode of action indicated that 10j effectively induced apoptosis in H1975 cells by arresting the cells in the G2/M phase. Compound 10j also demonstrated efficacy in inhibiting tumor growth in a H1975 xenograft mouse model without losing body weight or killing the mice. Taken together, these results suggested that 10j might be a promising candidate for development as a potential treatment for NSCLC harboring the EGFR mutation.Copyright © 2021 Elsevier Inc. All rights reserved.
About The Expert
Lixue Chen
Yunhao Zhang
Changyuan Wang
Zeyao Tang
Qiang Meng
Hunjun Sun
Yan Qi
Xiaodong Ma
Lei Li
Yanxia Li
Youjun Xu
References
PubMed